FIBA company, Aeye Health, receives FDA clearance

The Tel Aviv-based healthtech firm AEYE Health announced on Tuesday it has received clearance from the U.S. Food & Drug Administration to market its diagnostic screening system for diabetic retinopathy, a complication of diabetes caused by high blood sugar levels that can damage the retina and cause blindness if left undiagnosed. Instead of needing an annual appointment with an ophthalmologist for screening, AEYE patients will be able to receive initial screening from their primary care physician or at other healthcare facilities including retail pharmacies. Only patients for which the AI system detects potential disease need to be referred to a specialist. That clearance could be a game-changer for the millions of people who are at high risk of diabetic retinopathy (a condition that remains the top cause of blindness in the working-age population).

Read the full story:
jQuery( document ).ready(function() { add_action( 'resetpass_form', 'resettext'); function resettext(){ ?>